Survival Predictor For Diffuse Large B Cell Lymphoma

Brief Description

This invention provides methods and arrays related to a gene expression-based survival predictor for DLBCL patients, including patients treated with the current standard of care, which includes chemotherapy and the administration of Rituximab. The invention provides a method of predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL) that includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject. The gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a germinal center B cell (GCB) gene expression signature and each gene in a stromal- 1 gene expression signature.

 

URV Reference Number: 6-1842

Patent Information:
Category(s):
Diagnostic
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
585.276.6608
weimin.kaufman@rochester.edu
Inventors:
Richard Fisher
Lisa Rimza
Andrew Lister
Dennis Weisenburger
Jan Delabie
Erlend Smeland
Harald Holte
Stein Kvaloy
Rita Braziel
Pedro Jares
Armando Lopez-Guillermo
Elias Campo Guerri
Elaine Jaffe
Georg Lenz
Wyndham Wilson
George Wright
Sandeep Dave
Randy Gascoyne
Joseph Connors
Hans-Konrad Muller-Hermelink
Andreas Rosenwald
German Ott
Keywords: